Immunogenic compositions and uses thereof
AssigneePfizer Inc.
InventorsBridget Yih Jiin Huang, Weiqiang Li, Kena Anne Swanson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
Claims39
An RNA molecule comprising at least one open reading frame encoding a human Metapneumovirus (hMPV) fusion protein F (F) polypeptide and a 5′ untranslated region (5′ UTR), wherein the 5′ UTR comprises a nucleic acid sequence at least 90% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 336-344, 356-358, 360, 362-367, 370-375, and 378-396.
-4. (canceled)
An RNA molecule comprising at least one open reading frame encoding a parainfluenza virus type 3 (PIV3) fusion protein F (F) polypeptide and a 5′ untranslated region (5′ UTR), wherein the 5′ UTR comprises a nucleic acid sequence at least 90% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 336-344, 356-358, 360, 362-367, 370-375, and 378-396.
-8. (canceled)
An RNA molecule comprising at least one open reading frame encoding a parainfluenza virus type 3 (PIV3) hemagglutinin-neuraminidase protein (HN) polypeptide.
-13. (canceled)
An RNA molecule comprising at least one open reading frame encoding a parainfluenza virus type 1 (PIV1) fusion protein F (F) polypeptide and a 5′ untranslated region (5′ UTR), wherein the 5′ UTR comprises a nucleic acid sequence at least 90% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 336-344, 356-358, 360, 362-367, 370-375, and 378-396.
-18. (canceled)
An RNA molecule comprising at least one open reading frame encoding a parainfluenza virus type 1 (PIV1) hemagglutinin-neuraminidase protein (HN) polypeptide.
-31. (canceled)
(canceled)
-42. (canceled)
-47. (canceled)
(canceled)
(canceled)
-60. (canceled)
(canceled)
A mutant of a wild-type parainfluenza virus type 1 (PIV1) HN polypeptide, wherein the mutant comprises at least one amino acid mutation relative to the amino acid sequence of the wild type PIV1 HN polypeptide, wherein the mutation is selected from the group consisting of:
- i) a deletion of residues at positions 57-84;
- and ii) a deletion of residues at positions 57-129, wherein the amino acid positions are numbered according to SEQ ID NO:
- 750.
A mutant of a wild-type parainfluenza virus type 3 (PIV3) HN polypeptide, wherein the mutant comprises at least one amino acid mutation relative to the amino acid sequence of the wild type PIV3 HN polypeptide, wherein the mutation is selected from the group consisting of:
- i) a deletion of residues at positions 59-88;
- and ii) a deletion of residues at positions 59-130, wherein the amino acid positions are numbered according to SEQ ID NO:
- 724.
-71. (canceled)
Dependencies are inferred from the claim text.